60 Degrees Pharmaceuticals Inc (SXTP) USD0.0001

Sell:$0.58Buy:$0.61$0.02 (3.70%)

Prices delayed by at least 15 minutes
Sell:$0.58
Buy:$0.61
Change:$0.02 (3.70%)
Prices delayed by at least 15 minutes
Sell:$0.58
Buy:$0.61
Change:$0.02 (3.70%)
Prices delayed by at least 15 minutes

Company Information

About this company

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years of age and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.

Key people

Ll S. Dow
President, Chief Executive Officer, Director
Tyrone Miller
Chief Financial Officer
Kristen Landon
Chief Operating Officer
Cheryl Xu
Director
Charles W. Allen
Independent Director
Paul Field
Independent Director
Stephen Toovey
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US83006G2030
  • Market cap
    $3.93m
  • Employees
    3
  • Shares in issue
    5.42m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.